• Home Dutch
  •  EN 
  • Employee login

Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )

Print 
Title: Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
Supervisor:  P Denig
Summary:  The GIANTT project is a regional initiative of health care providers and researchers focusing on the care delivered to ambulant patients with type 2 diabetes mellitus in the north of the Netherlands. The goals are to improve the quality of care delivered to patients with type 2 diabetes mellitus and reduce complications and improve the quality of life for these patients. To reach these goals, the GIANTT project:
  • provides the organization, expertise and technical support to enable continuous monitoring of diabetes care based on routinely registered data;
  • offers benchmark reports to participating diabetes and primary care facilities using evidence based quality indicators (process and outcome indicators);
  • conducts scientific research to assess determinants of quality of care;
  • evaluates treatment compliance using prescription refill methods;
  • evaluates initiatives to improve the quality of care in (randomized) trials;  
  • conducts studies to assess the impact of (changes in) care on patient outcomes (including morbidity and mortality) in a routine care setting.   Financing: 1e/3e GS, Groninger Huisartsen Cooperatie, UMCG, Menzis
Start:  1-1-2004
End:  1-1-2013  

      

Projects
The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects